RESTON,
Va., Jan. 29, 2024 /PRNewswire/ -- Leidos
(NYSE:LDOS), a Fortune 500® innovation company, was recently
awarded a prime contract by the Advanced Research Projects Agency
for Health (ARPA-H). The hybrid firm fixed price/time and materials
contract was awarded by the U.S. Department of Health and Human
Services (HHS) and has a one-year base period of performance and
two one-year options.
"We are thrilled to work with ARPA-H building the infrastructure
and capabilities necessary to drive biomedical breakthroughs and
groundbreaking health discoveries," said Liz Porter, Leidos health and civil sector
president. "Leveraging our expertise in delivering health solutions
to improve health outcomes and efficiencies will empower ARPA-H as
the agency grows and evolves. We look forward to helping them
tackle the most pressing health challenges facing society
today."
ARPA-H supports the development of high-impact transformative
biomedical and health research as an independent entity of the
National Institutes of Health (NIH). Through this contract, Leidos
will provide scalable solutions and resilient systems to the
agency's mission accelerating better health outcomes for everyone.
The company will provide ARPA-H with a full range of IT support,
design, development, and implementation.
About Leidos
Leidos is a Fortune 500® innovation company rapidly addressing
the world's most vexing challenges in national security and health.
The company's 47,000 employees support vital missions for
government and commercial customers. Headquartered in Reston, Virginia, Leidos reported annual
revenues of approximately $14.4
billion for the fiscal year ended December 30, 2022. For more information, visit
www.leidos.com.
Certain statements in this announcement constitute
"forward-looking statements" within the meaning of the rules and
regulations of the U.S. Securities and Exchange Commission (SEC).
These statements are based on management's current beliefs and
expectations and are subject to significant risks and
uncertainties. These statements are not guarantees of future
results or occurrences. A number of factors could cause our actual
results, performance, achievements, or industry results to be
different from the results, performance, or achievements expressed
or implied by such forward-looking statements. These factors
include, but are not limited to, the "Risk Factors" set forth in
Leidos' Annual Report on Form 10-K for the fiscal year ended
December 30, 2022, and other such
filings that Leidos makes with the SEC from time to time. Readers
are cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date hereof. Leidos
does not undertake to update forward-looking statements to reflect
the impact of circumstances or events that arise after the date the
forward-looking statements were made.
Contact:
|
Melissa Dueñas
|
|
(571)
526-6850
|
|
duenasml@leidos.com
|
|
|
|
Alyssa
Pettus
|
|
(571)
526-6743
|
|
alyssa.t.pettus@leidos.com
|
|
|
|
Brandon
VerVelde
|
|
(571)
526-6257
|
|
Brandon.p.vervelde@leidos.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/leidos-awarded-contract-to-support-arpa-h-302047128.html
SOURCE Leidos Holdings, Inc.